Kronos Bio

38 articles about Kronos Bio

• Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance

  6/6/2023

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marc Besman Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance. 

• Kronos Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results

  8/12/2021

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, reported recent business progress and second quarter financial results.

• 

  Belldegrun's Third Fund Continues "Bold Investment Strategy" with $825 Million

  6/24/2021

  Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies. 

• Kronos Bio Announces Participation in Upcoming Investor Conferences - May 26, 2021

  5/26/2021

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that members of the management team will participate in fireside chats at the following investor conferences:

• Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today

  5/25/2021

  Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials in late 2021 and early 2022

• Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

  5/11/2021

  Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform

• Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

  5/6/2021

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 p.m. ET.

• Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021

  4/10/2021

  Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter of 2021

• Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.

  3/31/2021

  Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the company.

• Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors

  3/26/2021

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Taiyin Yang, Ph.D., to the company’s board of directors.

• Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

  3/10/2021

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that data from a pre-clinical study of KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors, will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2021,

• Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)

  3/4/2021

  Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval First time MRD could serve as the basis for regulatory approval in AML Trial to begin in mid-2021, with MRD negative CR data expected in second half of 2023

• Kronos Bio Announces Participation in the Cowen 41st Annual Health Care Conference

  2/22/2021

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the Cowen 41 st Annual Health Care Conference, a virtual event taking place March 1-4, 2021.

• Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

  1/26/2021

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of veteran biopharmaceutical executive Marianne De Backer, Ph.D., to the company’s board of directors. She has more than two decades of experience in business development and commercial leadership in the healthcare industry. Additionally, the company announced that Rebecka Belldegrun

• Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

  12/7/2020

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced U.S. Food and Drug Administration (FDA) clearance of the company’s Investigational New Drug (IND) application for KB-0742, a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9)

• Kronos Bio Announces Participation in Upcoming Investor Conferences

  11/23/2020

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in the following investor conferences: A virtual fireside chat at the Evercore ISI 3 rd Annual HealthCONx Conference on Wednesday, Dec. 2, 2020, at 2:15 p.m. ET; and Meetings at the Piper Sandler 32 nd Annual Virtual Healthcare Conference o

• Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results

  11/18/2020

  Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia Expanded executive team and board of directors with hiring of COO and CFO and appointment of audit committee chair, respectively Completed upsized initial public offering of common stock on October 14, 2020, raising $28 7.5 million in gross proceeds

• Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare Conference

  11/11/2020

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Wednesday, Nov. 18, 2020, at 7:20 p.m. GMT (2:20 p.m. ET).

• Kronos Bio Announces Publication of Preclinical Study Results for Investigational CDK9 Inhibitor KB-0742 in Cell Chemical Biology

  10/22/2020

  KB-0742 is a transcription regulatory network modulator discovered using the company’s proprietary high - throughput screening platform Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer Company is on t rack to s ubmit an  IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial

• Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  10/14/2020

  Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the closing of its previously announced initial public offering of 15,131,579 shares of its common stock, which includes 1,973,684 shares sold pursuant to the exercise in full by t